Intraoral dosing method of administering trifluorobenzodiazepines, propoxyphene, and nefazodone

Patent 5504086 Issued on April 2, 1996. Estimated Expiration Date:

October 11, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Antidepressant 1,2,4-triazolone compounds Patent #: 4613600
Issued on: 09/23/1986
Inventor: Gammans , et al.

Inventors

Application

No. 321246 filed on 10/11/1994

US Classes:

514/254.05Plural nitrogens in the additional five-membered hetero ring

Examiners

Primary: Criares, Theodore J.

Attorney, Agent or Firm

Jenkins; Richard E.

International Classes

A61K 031/495
A61K 031/50

Abstract

A method of therapeutically administering certain BZ1 specific trifluorobenzodiazepines in order to maximize the BZ1 effects and minimize the BZ2 effects on the human central nervous system in order to maximize the anti-anxiety, anticonvulsant and hypnotic effects and minimize the ataxic and incoordination effects of the drug. Also, a method of sublingual administration of trifluorobenzodiazepines and certain other compounds, such as propoxyphene and nefazodone, in order to decrease unwanted metabolites.

Other References

Zohar et al., "Serotonergic Responsivity in Obsessive-Compulsive Disorder", Arch Gen Psychiatry, vol. 44, pp. 946-951 (Nov. 1987)
Kahn et al., "Behavioral Indications for Serotonin Receptor Hypersensitivity in Panic Disorder", Psychiatry Research, vol. 25, pp. 101-104 (1988)
Hollander et al., "Serotonergic and Noradrenergic Sensitivity in Obsessive-Compulsive Disorder: Behavioral Findings", American Journal of Psychiatry, vol. 145:8, pp. 1015-1017 (Aug. 1988)
Walsh et al., "Neuroendocrine and Temperature Effects of Nefazodone in Healthy Volunteers", Biological Psychiatry, vol. 33, pp. 115-119 (1993)
Shukla et al., "Pharmacokinetics, Absolute Bioavailability, and Disposition of ¹⁴ C! Nefazodone in the Dog", Drug Metabolism and Disposition, vol. 21, No. 3, pp. 502-507 (1993)
Shukla et al., "Pharmacokinetics of Nefazodone Following Multiple Escalating Oral Doses in the Dog", European Journal of Drug Metabolism and Pharamcokinetics, vol. 17, No. 4, pp. 309-318 (1992